Sun Pharma Advanced Research Company (SPARC) has received Securities and Exchange Board of India’s (Sebi’s) approval to raise up to Rs 250 crore through a rights issue. The company, which filed draft papers on September 18, 2015 seeking clearance from the markets regulator to raise funds through a rights issue, obtained the approval on January 22, 2016. The company will issue equity shares ‘aggregating up to Rs 25000 lakh to its existing equity shareholders on a rights basis. In a rights issue, shares are issued to existing investors as per their holding at a pre-determined price and ratio.
Sun Pharma Advanced Research Company is an international pharmaceutical company engaged in research and development of drugs and delivery systems.
| Company Name | CMP |
|---|---|
| Syngene Internation. | 435.70 |
| Indegene | 486.80 |
| CMS Info Systems | 318.00 |
| JITF Infralogistics | 338.00 |
| Sagility | 42.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: